Elmiron Legal Claim
Elmiron® (pentosan polysulfate sodium) is the topic of a recent legal claim that highlights the connection of this dangerous drug to a collection of serious vision problems. People who have suffered eye damage related to this medication may qualify to file a legal claim against Elmiron to pursue financial compensation for damages. To determine eligibility to file a claim, contact Action Legal Group for a free review of your case.
Elmiron is a prescription medication used to offer a patient relief from bladder pain and discomfort exacerbated by interstitial cystitis (IC). This is a chronic bladder condition that causes recurring pain in the bladder or the surrounding pelvic area. The medication has faced scrutiny for its link to eye damage. Patients who have taken Elmiron claim that the drug may have cause multiple vision issues.
A single Elmiron lawsuit that was filed in March 2020 alleges that the drug manufacturer failed to disclose a link between the IC medication use and substantial vision damage.
If you or a family member take this dangerous bladder medication and have suffered vision damage as a result, you may have be able to file a legal claim.
Pentosan polysulfate sodium (Elmiron) was approved by the U.S. FDA in 1996 and it remains the only FDA-approved oral medication to treat bladder pain and discomfort associated with interstitial cystitis. The chronic condition is one part of a spectrum of medical conditions known as painful bladder syndrome. There is no cure for this bladder condition.
Recent scientific studies have researched the link between the IC medication Elmiron and vision damage.
Elmiron may be linked to the following eye diseases:
Additional Elmiron side effects can include:
If you or a family member used this bladder discomfort medication and have since suffered vision impairment, you may be eligible to file an Elmiron claim.
For additional information, contact Action Legal Group today. The Elmiron case managers on our team are available 24/7 to answer questions about Elmiron claims and provide additional support.
Below you will find some of the questions we have encountered about the dangerous medication Elmiron.
The medication is not a cure for interstitial cystitis. There are currently only medical treatments that will lessen or relieve the pain and ongoing symptoms related to IC, but Elmiron on its own will not cure the medical disorder.
It is not unusual for an IC patient to undergo different therapies to identify the right combination that will provide the patient relief. For almost half of interstitial cystitis patients, symptoms may disappear on their own.
For a bladder pain patient who starts an Elmiron regimen, it may require 3 – 6 months of treatment before a patient notices signs of pain relief.
After the initial 3 months, the medical case should be reviewed by the doctor. Depending on the efficacy of the drug and the absence of any side effects, your doctor may then recommend continuing the Elmiron use for another 3 – 6 months.
Elmiron patients who react well to the medication may continue using the medication up to 15 – 20 years or longer.
In recent scientific studies, clinical researchers have been able to identify a direct link between the use of the medication and macular degeneration.
In a study from 2019, nearly 100 IC patients who had taken the drug for 15 years were tested for problems with their vision. A total of 22 IC patients in the sample population had clear indications of retinal damage associated with macular degeneration.
Maculopathy is another name for the for macular degeneration. This is an eye condition that affects the central part of your retina, the part that is responsible for delivering accurate vision. This retinal condition is characterized by an ongoing loss of central vision, it greatly impairs vision functions.
Patients suffering from maculopathy or macular degeneration feel no pain. It is possible medication users may not even notice any changes to vision, because the unaffected eye compensates for the damage.
The initial symptoms of include:
These symptoms can lead to:
The medication Elmiron is currently the only FDA-approved medication for the treatment of interstitial cystitis.
While there are no other FDA-approved medications for this medical condition, many physicians treat IC patients with a combination of methods that can include modifications to diet and OTC pain relievers like ibuprofen.
The existing criteria for filing an Elmiron injury lawsuit requires:
IC patients need to have used the prescription medication Elmiron for a period of at least 2 years
Documented vision changes and medication side effects need to begin while on the IC medication or need to take place within one year of stopping Elmiron.
A 2020 Elmiron legal claim alleges that the manufacturer did not reveal the link between Elmiron and serious damage to the vision of people prescribed the medication and failed to warn patients about the potential risk.
Given that the sale of Elmiron amounts to at least $150 Million each year and it is the only FDA-approved medication on the market, a substantial population of Americans may be at risk for developing vision loss.